A detailed history of D. E. Shaw & Co., Inc. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 757,731 shares of FULC stock, worth $3.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
757,731
Holding current value
$3.3 Million
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.18 - $9.74 $527,708 - $1.62 Million
165,946 Added 28.04%
757,731 $2.71 Million
Q2 2024

Aug 14, 2024

SELL
$5.98 - $9.31 $199,678 - $310,870
-33,391 Reduced 5.34%
591,785 $3.67 Million
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $854,229 - $1.53 Million
127,497 Added 25.62%
625,176 $5.9 Million
Q4 2023

Feb 14, 2024

BUY
$3.18 - $6.86 $878,999 - $1.9 Million
276,415 Added 124.93%
497,679 $3.36 Million
Q3 2023

Nov 14, 2023

BUY
$3.25 - $6.08 $243,886 - $456,255
75,042 Added 51.32%
221,264 $982,000
Q2 2023

Aug 14, 2023

BUY
$2.26 - $3.8 $295,831 - $497,416
130,899 Added 854.26%
146,222 $482,000
Q1 2023

May 15, 2023

SELL
$2.83 - $13.99 $455,129 - $2.25 Million
-160,823 Reduced 91.3%
15,323 $43,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $469,973 - $783,288
93,807 Added 113.93%
176,146 $1.28 Million
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $281,143 - $520,001
-57,143 Reduced 40.97%
82,339 $666,000
Q2 2022

Aug 15, 2022

SELL
$4.2 - $24.0 $1.71 Million - $9.79 Million
-407,922 Reduced 74.52%
139,482 $683,000
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $3.04 Million - $7.21 Million
-304,744 Reduced 35.76%
547,404 $12.9 Million
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $756,658 - $1.54 Million
54,047 Added 6.77%
852,148 $15.1 Million
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $5.81 Million - $24.7 Million
798,101 New
798,101 $22.5 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $226M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.